Summary
Background
LT-001 evaluated long-term safety/efficacy of onasemnogene abeparvovec (OA) for spinal muscular atrophy (SMA) patients from START (N = 15; NCT02122952).
Methods
Reported is an interim analysis (5-year totalling up to 10-years post-dose) of long-term follow-up data from START (phase 1, open-label, single-arm, dose-escalation; 2-year follow-up [Nationwide Children's Hospital, Columbus, Ohio] [first patient dosed: May 5, 2014]). Patients (symptomatic SMA type 1, biallelic SMN1 mutations/deletions, two SMN2 copies; full analysis set) received single intravenous OA dose (low [6·7 × 1013 vg/kg] or proposed therapeutic dose [equivalent to 1·1 × 1014 vg/kg]). Safety (primary outcome) and efficacy (alive and independent of permanent ventilatory support [post hoc]) were assessed (NCT03421977 [September 21, 2017–September 17, 2018]).
Findings
The LT-001 study was initiated on September 21, 2017, and the last patient was enrolled on September 17, 2018. As of July 1, 2024, 13 START patients enrolled in LT-001 (n = 3/13, low-dose; n = 10/13, therapeutic-dose). Mean (SD); min–max age at dosing was 6·3 (0·7); 5·8–7·1 months (low-dose) and 2·8 (1·5); 0·9–5·6 months (therapeutic-dose). Mean (SD); min–max follow-up duration was 9·9 (0·2); 9·8–10·1 years (low-dose) and 8·3 (1·1); 6·8–9·6 years (therapeutic-dose). Most patients (≥70%) received nusinersen/risdiplam post-dosing. Serious adverse events (n = 11/13; 85%) were most frequently acute respiratory failure, dehydration, and pneumonia (none led to study discontinuation or death). Six adverse events (AEs) of special interest (n = 4/13; 31%) included transient thrombocytopenia, cardiac AEs, and new incidence of neurologic disorders (unrelated to treatment). All (n = 13/13) were alive at last visit (n = 5 therapeutic-dose) or data cutoff (n = 8 ongoing). The majority (n = 12/13) were free of permanent ventilation.
Interpretation
OA demonstrated a favourable benefit–risk profile and efficacy up to 10 years for START/LT-001 patients, though there are limitations (descriptive analyses, small population, add-on therapy, lack of comparator). Further long-term research may build on phase 3/4 study findings with OA for SMA patients.
Funding
Novartis Pharma AG.
Keywords: Gene therapy, Onasemnogene abeparvovec, Long-term follow-up, Neuromuscular disease, Spinal muscular atrophy
Research in context.
Evidence before this study
While real-world studies like the RESTORE registry aim to provide follow-up data, long-term clinical trial data are lacking for onasemnogene abeparvovec outcomes for patients with spinal muscular atrophy (SMA), and specifically for symptomatic patients with SMA type 1, as indicated by a literature search with no references found starting from September 1, 2017 (PubMed database; search terms included “onasemnogene abeparvovec long-term spinal muscular atrophy treatment”). Symptomatic SMA type 1 patients in the START study, a phase 1, open-label, single-arm, dose-escalation trial with 2-year follow-up (N = 15; NCT02122952), demonstrated continued efficacy (e.g., motor function improvements, motor milestone demonstrations) and safety, with ventilation-free survival at 20 months of age (n = 13/13), compared with a rate of survival of 8% in a natural history cohort. Continuous monitoring and follow-up are needed to evaluate the long-term safety and efficacy of onasemnogene abeparvovec.
Added value of this study
The long-term follow-up LT-001 study (NCT03421977) expands on safety and efficacy data for intravenous onasemnogene abeparvovec in patients from START. This 5-year LT-001 data cut provides the opportunity to report on up to 10-year post-dose data for the safety and efficacy of onasemnogene abeparvovec for patients with symptomatic SMA type 1.
Implications of all the available evidence
The LT-001 study results provide support for the favourable benefit–risk profile of onasemnogene abeparvovec in the treatment of symptomatic patients with SMA type 1. A single intravenous dose of onasemnogene abeparvovec demonstrated sustained efficacy with or without add-on therapy, and no treatment-related late-onset serious AEs or AEs of special interest for up to 10 years post-dose for patients with symptomatic SMA type 1. Results should be interpreted in the context of limitations (e.g., small sample size, lack of comparator arm, and add-on therapy for some patients); further research is needed to support these findings in a larger population.
Introduction
Spinal muscular atrophy (SMA) is a rare, debilitating, neuromuscular disease caused by biallelic pathogenic variants in the survival motor neuron 1 (SMN1) gene.1,2 The global incidence of SMA is approximately one in 15,000 live births.3,4 SMA is characterised by irreversible and progressive motor neuron loss, resulting in muscle weakness, hypotonia, difficulties with feeding and respiration, and, in the most severe untreated cases, infantile death occurs before 2 years of age.2
SMA was historically classified into five clinical types based on age at onset and maximum motor milestone demonstrated.5,6 SMA type 1 is the most severe and common form of the disease, affecting 50%–60% of patients with SMA.7 Individuals most at risk for SMA type 1 are those who have SMN1 biallelic deletions and two copies of the survival motor neuron 2 (SMN2) gene, which produces minimal stable SMN protein as a backup to SMN1.8 Average symptom onset for patients with SMA type 1 occurs at 2·5 months of age. Despite some initial motor milestone demonstration (e.g., head control or rolling), patients with SMA type 1 decline in motor function by 6 months of age. Before the availability of current disease-modifying treatments, SMA type 1 was associated with premature death, with a median survival of 6–8 months, or the need for permanent ventilation by 2 years of age.9, 10, 11
For patients with SMA type 1, treatment outcomes focus on event-free survival, as well as overall safety and efficacy in improving motor function and preventing progressive decline. There are currently three approved treatments for patients with SMA: nusinersen and risdiplam, both SMN2-targeting treatments, and onasemnogene abeparvovec, a one-time, intravenous, adeno-associated virus 9 (AAV9) vector-based gene replacement therapy that delivers a fully functional copy of the human SMN1 complementary DNA into target cells and is designed to enable rapid and continuous expression of SMN protein.12, 13, 14 These treatments have substantially increased survival for patients with SMA; however, the long-term implications are not yet well understood.15 Although presymptomatic treatment is ideal for prevention of motor decline and symptom development, symptomatic patients may also benefit from treatment.16,17
The phase 1 START study (open-label, single-arm, dose-escalation trial with 2-year follow-up, N = 15; NCT02122952) and subsequent long-term follow-up LT-001 study (NCT03421977) were designed to assess the safety and efficacy of intravenous onasemnogene abeparvovec for symptomatic patients with SMA type 1. In START, patients were treated with either a low dose or the proposed therapeutic dose of onasemnogene abeparvovec. All patients (N = 15) demonstrated ventilation-free survival at 20 months of age. Further, patients treated with the therapeutic dose of onasemnogene abeparvovec exhibited improvements in motor function and the demonstration of motor milestones, including two patients who demonstrated the ability to walk independently (n = 12).18,19 Five-year extension results demonstrated continued safety and efficacy for the 13 patients enrolled from START, with all patients in the therapeutic-dose cohort (n = 10/10) and two of three patients in the low-dose cohort surviving and without the need for permanent ventilation.20 All 10 patients treated with the therapeutic dose were able to continue to demonstrate motor milestones that were attained in START; some patients demonstrated new motor milestones.
Continuous monitoring and follow-up are needed to evaluate the long-term safety and efficacy of onasemnogene abeparvovec. We present extended LT-001 follow-up data of up to 10 years post-dose, with the objective of assessing the long-term safety and efficacy of onasemnogene abeparvovec for symptomatic patients with SMA type 1.
Methods
Study design
Following completion of the START study with patients from the Nationwide Children's Hospital in Columbus, Ohio, patients were invited to enrol in the long-term follow-up LT-001 study (NCT03421977) for ongoing safety and efficacy monitoring for up to 15 years from the date of intravenous onasemnogene abeparvovec dosing (Supplementary Figure S1).21 Patients were grouped by onasemnogene abeparvovec dose: low-dose cohort (6·7 × 1013 vg/kg) and the proposed therapeutic-dose cohort (hereafter referred to as the “therapeutic-dose cohort”—equivalent to 1·1 × 1014 vg/kg). The equivalent value for the proposed therapeutic dose reported for LT-001 differs from that of START (2·0 × 1014 vg/kg) owing to the use of new, more accurate, and validated measurement methods (droplet digital polymerase chain reaction [ddPCR] versus quantitative PCR [qPCR]). Interim analysis data for the full analysis set of enrolled patients are reported here (July 1, 2024, data cutoff). The study adhered to CONSORT reporting guidelines.
Ethics
The study protocol and all amendments were reviewed and approved by the Institutional Review Board at the participating institution (Nationwide Children's Hospital, Columbus, OH, USA) (AVXS-101-LT-001 [COAV101A12401]).20 A summary of protocol amendments is included in Supplementary Table S1. The study was conducted according to International Council for Harmonisation (ICH) E6 Guidelines for Good Clinical Practice (GCP) that have their origin in the Declaration of Helsinki.
Informed consent was obtained from parent(s)/guardian(s) of the patients in writing before any study-specific procedure was performed. Informed consent for the LT-001 study was completed at the last visit in START or, if patients discontinued from START, they had the opportunity to provide informed consent for enrolment in LT-001, if desired, at the last visit requesting early discontinuation. The study was explained to the parent(s)/guardian(s) of the patients by the investigator or designee, who answered any questions, and written information was also provided.
Patients
Patients enrolled in LT-001 had symptomatic SMA type 1, biallelic SMN1 mutations or deletions, and two SMN2 copies. Patients were included if they had received onasemnogene abeparvovec in START, had a parent or legal guardian who completed the informed consent process, and were willing and able to comply with study procedures and visit schedule.
Randomisation and masking
No randomisation or masking occurred in this study.
Procedures
The LT-001 study consisted of an initial 5-year period of in-person annual study visits followed by an observational phase, during which patients are contacted annually via telephone for up to an additional 10 years. This follow-up analysis was prespecified as part of the study protocol.20 Caregivers of patients responded to questionnaires administered by site staff over the telephone during the observational phase. Questionnaires were designed to elicit information regarding medical history, safety, and other clinical information. In addition, record transfers from patients’ local physicians and/or neurologists were requested as necessary in conjunction with the annual phone contacts for review by the investigator.
All study visits, procedures, and assessments were performed or completed in accordance with the schedule of assessments. For in-person study visits, assessments could occur over 1–7 days. For instances where it was not possible for the final scheduled in-person study visit to be conducted at the study site, these visits were conducted remotely within the protocol-defined visit window. Procedures such as laboratory and other safety assessments not able to be conducted remotely were performed separately and preferably within the protocol-defined visit window. Any treatment for SMA other than onasemnogene abeparvovec was listed and summarised according to the World Health Organization (WHO) Drug Dictionary. The LT-001 study was initiated on September 21, 2017, and the last patient was enrolled on September 17, 2018.
Outcomes
Safety
Long-term safety of onasemnogene abeparvovec for patients with SMA type 1 treated in START was assessed as the primary outcome. Serious adverse events (SAEs) and adverse events of special interest (AESI) were reported by the investigators based on medical history and examination as defined in the LT-001 study protocol. Adverse events (AEs) were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 27·0. The number and percentage of patients with SAEs were summarised along with the total number of unique events by cohort, primary system organ class, preferred term, and maximum severity for SAE. AESI comprised hepatotoxicity, thrombotic microangiopathy, cardiac AEs, dorsal root ganglia toxicity, transient thrombocytopenia, new malignancies, and potential gene therapy-related delayed AEs (new incidence of neurologic disorders, new incidence of autoimmune disorders, new incidence of haematologic disorders). Broad search criteria were applied to retrieve events with the aim to increase the likelihood of capturing AEs that may be related to onasemnogene abeparvovec treatment as per the investigator, albeit with reduced specificity. AESI were summarised by cohort, AESI category, and preferred term.
Clinical laboratory evaluations included collection of blood samples for haematology and clinical chemistry analyses. Other safety assessments included physical examination, evaluation of vital signs, electrocardiogram (ECG), and echocardiogram. Vital sign measurements included blood pressure, respiratory rate, pulse, axillary temperature, and pulse oximetry. Neurologic examinations included detailed, age-appropriate sensory testing (such as examination of proprioceptive, vibratory, tactile, and pain sensation). For ECG and echocardiogram, data collected at the first visit after patients enrolled in LT-001 were treated as baseline values.
Efficacy
The post-hoc efficacy objective was to assess the number and percentage of patients who were alive and remained independent of permanent ventilatory support at the end of the initial 5-year follow-up phase. Permanent ventilatory support was defined as invasive ventilation or ≥16 h/day of non-invasive ventilation support for ≥14 days in the absence of an acute reversible illness or perioperatively.
Other objectives included demographics, medical history, and concomitant medications for SMA, ventilatory support requirements, nutrition or feeding support requirements, and demonstration of developmental motor milestones according to a sponsor-created developmental milestone checklist containing nine items (Supplementary Table S2). The developmental motor milestone checklist item criteria were defined per the WHO Multicentre Growth Reference Study (WHO MGRS) criteria or Bayley Scales of Infant and Toddler Development, 3rd edition.22,23
Data analysis
The primary analysis was performed after all patients completed the 5-year visits or their last visit before study withdrawal. This manuscript is based on an interim analysis, which was performed after all patients completed the initial 5-year follow-up phase. No hypothesis testing was performed. Data were summarised descriptively as the number and percentage of patients by cohort and overall. The full analysis set, which included all patients who were enrolled in LT-001 and received onasemnogene abeparvovec, was used for all summaries of data. No imputation for missing data was implemented for any data collected for the main analysis.
Data quality assurance
During the study, a monitor from Novartis or a representative remained in contact with the investigational site to provide information and support to the investigators, to confirm that the facilities remained acceptable, to confirm that the investigational team was adhering to the protocol and ICH GCP guidelines, and to confirm that data were being accurately recorded in the electronic case report forms including performing source data verification, recording and reporting any protocol deviations not previously sent to Novartis, and confirming that SAEs and AESI were properly documented.
Role of the funding source
All financial and material support for this research was provided by Novartis Pharma AG, Basel, Switzerland. The funder was involved in the study design, data collection, data analysis, data interpretation, and/or writing of this manuscript. All authors had full access to the data in the study. MAW, RBE, LY, RAC, ECB, LM, AI, and AMC had final responsibility for the decision to submit for publication.
Results
Patients
Thirteen of the 15 patients enrolled in START, (n = 3/13, low-dose cohort; n = 10/13, therapeutic-dose cohort) were enrolled in the LT-001 study (Fig. 1). Five patients, all from the therapeutic-dose cohort, discontinued the study at different times. Reasons for discontinuation were that the patient was lost to follow-up (n = 2/10) or that the parent or legal guardian withdrew consent (n = 3/10). As of July 1, 2024, eight patients remained enrolled (n = 3/3, low-dose cohort; n = 5/10, therapeutic-dose cohort). All eight patients (n = 13/13) completed at least 5 years of in-person study visits in LT-001 in addition to the 2 years of follow-up in the START study. Patients were followed for up to 10·1 (mean [SD]; min–max, 9·9 [0·2]; 9·8–10·1) years in the low-dose cohort and up to 9·6 (mean [SD]; min–max, 8·3 [1·1]; 6·8–9·6) years in the therapeutic-dose cohort (Table 1), with the total time of follow-up including the totals across both the START and LT-001 studies. For reference, the first patient to receive onasemnogene abeparvovec in START was dosed on May 13, 2014.
Fig. 1.
Patient disposition. Data were unavailable with regard to rationale for two patients who did not enrol in LT-001 from the START study.
Table 1.
Patient demographics and baseline disease characteristics.
| Characteristic | Low dose (n = 3) | Therapeutic dose (n = 10) | Total (N = 13) |
|---|---|---|---|
| Age | |||
| At symptom onset, months | |||
| Mean (SD) | 1·7 (1·2) | 1·2 (0·9) | 1·3 (0·9) |
| Min–max | 1·0–3·0 | 0·0–3·0 | 0·0–3·0 |
| At dosing, months | |||
| Mean (SD) | 6·3 (0·7) | 2·8 (1·5) | 3·6 (2·0) |
| Min–max | 5·8–7·1 | 0·9–5·6 | 0·9–7·1 |
| At baseline (LT-001 enrolment), years | |||
| Mean (SD) | 3·7 (0·2) | 2·8 (0·6) | 3·0 (0·7) |
| Min–max | 3·6–3·9 | 2·1–3·8 | 2·1–3·9 |
| Weight at baseline (LT-001 enrolment), kg | |||
| Mean (SD) | 13·2 (1·4) | 11·9 (1·3) | 12·2 (1·4) |
| Min–max | 12·0–14·7 | 10·0–14·6 | 10·0–14·7 |
| Follow-up time post-dose, years | |||
| Mean (SD) | 9·9 (0·2) | 8·3 (1·1) | 8·7 (1·2) |
| Min–max | 9·8–10·1 | 6·8–9·6 | 6·8–10·1 |
| Sex, n (%) | |||
| Male | 1 (33) | 5 (50) | 6 (46) |
| Female | 2 (67) | 5 (50) | 7 (54) |
| Ethnicity, n (%) | |||
| Hispanic or Latino | 0 | 2 (20) | 2 (15) |
| Not Hispanic or Latino | 3 (100) | 8 (80) | 11 (85) |
| Race, n (%)a | |||
| White | 3 (100) | 9 (90) | 12 (92) |
| Other | 0 | 1 (10) | 1 (8) |
| Baseline SMA symptoms, n (%) | |||
| Hypotonia | 3 (100) | 10 (100) | 13 (100) |
| Limb weakness | 3 (100) | 9 (90) | 12 (92) |
| Pneumonia or respiratory syndrome | 2 (67) | 8 (80) | 10 (77) |
| Swallowing or feeding difficulties | 3 (100) | 6 (60) | 9 (69) |
| Tongue fasciculations | 0 | 4 (40) | 4 (31) |
| Other | 1 (33) | 3 (30) | 4 (31) |
| Patient-reported ventilatory support, n (%) | |||
| Yes | 3 (100) | 4 (40) | 7 (54) |
| No | 0 | 6 (60) | 6 (46) |
| Patient-reported feeding support, n (%) | |||
| Yes | 3 (100) | 5 (50) | 8 (62) |
| No | 0 | 5 (50) | 5 (39) |
mo, month; SD, standard deviation; SMA, spinal muscular atrophy.
Other race categories for selection included American Indian or Alaska Native, Asian, African American, and Native American or Pacific Islander.
All 13 patients had at least one protocol deviation. Reasons for protocol deviation were assessment was not done (n = 11/13), missed study visit (n = 3/13), visit out of window (n = 3/13), missing laboratory parameters (n = 2/13), data collected before informed consent form signature (n = 1/13) (owing to reconsent on an updated informed consent form not being done in a timely manner), other (n = 1/13), and visit out of window/assessment not done (n = 1/13).
Of the 13 patients enrolled in LT-001, seven were female and six were male. Twelve patients were White, and the race of the remaining patient was reported as “Other” (Table 1). Mean (SD); min–max age at dosing was 6·3 (0·7); 5·8–7·1 months (low-dose cohort) and 2·8 (1·5); 0·9–5·6 months (therapeutic-dose cohort). The mean (SD); min–max age at baseline (enrolment into LT-001) was 3·7 (0·2); 3·6–3·9 years (low-dose cohort) and 2·8 (0·6); 2·1–3·8 years (therapeutic-dose cohort). Patients reported SMA symptoms at baseline (enrolment into LT-001), most commonly hypotonia (n = 13/13) and limb weakness (n = 12/13). Other frequently reported SMA symptoms presented at baseline included pneumonia or respiratory syndrome (n = 10/13) and swallowing or feeding difficulties (n = 9/13). At baseline, ventilatory support was reported for all three patients in the low-dose cohort and for four patients in the therapeutic-dose cohort. At baseline, feeding support was reported for all three patients in the low-dose cohort and for five patients in the therapeutic-dose cohort.
Most patients received nusinersen and/or risdiplam after they completed the START study and before or during LT-001 (n = 3/3, low-dose cohort; n = 7/10, therapeutic-dose cohort) (Supplementary Table S3). At data cutoff or at last visit for patients who discontinued the study, the use of risdiplam was ongoing for all but one patient, who was in the therapeutic-dose cohort.
Safety
SAEs and AESI
SAEs were reported for 11 patients (85%) after enrolment into the LT-001 study, none of which were considered related to onasemnogene abeparvovec treatment (Table 2). No SAEs led to study discontinuation or death. The most frequently reported SAEs were acute respiratory failure (n = 2/3 [67%], low-dose cohort; n = 4/10 [40%], therapeutic-dose cohort), dehydration (n = 1/3 [33%], low-dose cohort; n = 4/10 [40%], therapeutic-dose cohort), and pneumonia (n = 1/3 [33%], low-dose cohort; n = 4/10 [40%], therapeutic-dose cohort) (Supplementary Table S4).
Table 2.
Safety summary.
| Patients with SAEs or AESI, n (%) | Low dose (n = 3) | Therapeutic dose (n = 10) | Total (N = 13) |
|---|---|---|---|
| SAEs | 3 (100) | 8 (80) | 11 (85) |
| Related to onasemnogene abeparvovec | 0 | 0 | 0 |
| Leading to study discontinuation | 0 | 0 | 0 |
| Leading to death | 0 | 0 | 0 |
| Severe SAEs | 3 (100) | 8 (80) | 11 (85) |
| AESI | 2 (67) | 2 (20) | 4 (31) |
| Transient thrombocytopenia | 2 (67) | 0 | 2 (15) |
| Gastrointestinal haemorrhage | 1 (33) | 0 | 1 (8) |
| Procedural haemorrhage | 1 (33) | 0 | 1 (8) |
| Cardiac AEs | 1 (33) | 1 (10) | 2 (15) |
| Cardiac arrest | 1 (33) | 0 | 1 (8) |
| Dyspnoea | 0 | 1 (10) | 1 (8) |
| New incidence of neurologic disordersa | 0 | 2 (20) | 2 (15) |
| Anal incontinence | 0 | 1 (10) | 1 (8) |
| Muscular weakness | 0 | 1 (10) | 1 (8) |
| Hepatotoxicity | 0 | 0 | 0 |
| Transient microangiopathy | 0 | 0 | 0 |
| Dorsal root ganglia toxicity | 0 | 0 | 0 |
| New incidence of autoimmune disordersa | 0 | 0 | 0 |
| New incidence of haematologic disordersa | 0 | 0 | 0 |
AE, adverse event; AESI, adverse event of special interest; SAE, serious adverse event.
New incidences of neurologic, autoimmune, and haematologic disorders were defined as AESI for this study in line with regulatory requirements to capture these events in long-term follow-up studies after administration of human gene therapy products. These are not known risks with onasemnogene abeparvovec.
Four patients (31%) reported AESI in the categories of transient thrombocytopenia (n = 2/3 [67%], low-dose cohort), cardiac AEs (n = 1 per cohort), and new incidence of neurologic disorders (n = 2/10 [20%], therapeutic-dose cohort) (Table 2).
The AESI in the category of transient thrombocytopenia were gastrointestinal haemorrhage and procedural haemorrhage, each reported in one patient. Both patients recovered. These events were assessed by the investigators as unrelated to treatment, and no other potential causes for these events were documented by the investigators. Neither of the two events was associated with low platelet count.
Cardiac AEs included an event of cardiac arrest (n = 1/3 [33%]) reported in a patient in the low-dose cohort, and an event of dyspnoea (n = 1/10 [10%]) reported in a patient in the therapeutic-dose cohort, 305 and 135 days after enrolment in the long-term study, respectively. Both events were reported in settings of acute respiratory failure and resolved within 1 and 6 days, respectively.
New incidence of neurologic disorders included anal incontinence (n = 1/10 [10%]) and muscular weakness (n = 1/10 [10%]).
None of the AESI were considered to be related to onasemnogene abeparvovec treatment as per the investigator. There were no reports of hepatotoxicity, thrombotic microangiopathy, dorsal root ganglia toxicity, new malignancies, or new incidence of haematologic or autoimmune disorders.
Clinical laboratory evaluation: haematology and clinical chemistry
One patient in the therapeutic-dose cohort had a shift in grade (Grade 0 to Grade 2) for haemoglobin decreased at the end of the 5-year follow-up visits. Another patient in the therapeutic-dose cohort had alanine aminotransferase (ALT) >2 × upper limit of normal (ULN) (but <3 × ULN) at Year 2. This patient's ALT remained normal at subsequent study visits through the end of the 5-year follow-up. No patients had elevations in ALT or aspartate aminotransferase (AST) >3 × ULN, and no patient had total bilirubin >2 × ULN. No patient met Hy's Law criteria.
Other safety assessments: vital signs, neurologic examination, ECG, echocardiogram
The majority of patients had vital signs values that met the criteria for potential clinical significance at least once during the 5-year follow-up period (Supplementary Table S5). Clinically significant vital sign values were indicated as follows: high systolic blood pressure (n = 1/3 [33%], low-dose cohort; n = 10/10 [100%], therapeutic-dose cohort), high diastolic blood pressure (n = 1/3 [33%], low-dose cohort; n = 9/10 [90%], therapeutic-dose cohort), high pulse rate (n = 2/3 [67%], low-dose cohort; n = 8/10 [80%], therapeutic-dose cohort), and high respiratory rate (n = 2/3 [67%], low-dose cohort; n = 6/10 [60%], therapeutic-dose cohort). No AEs corresponding to vital signs abnormalities were reported.
No clinically significant abnormalities for neurologic, ECG, or echocardiogram findings were reported during the study. Any findings from the neurologic examinations were related to the diagnosis of SMA.
Efficacy
Event-free survival
As of the data cutoff or at last visit before discontinuation, all patients (n = 13/13 [100%]) were alive, which included eight patients who were ongoing in the study and five patients who discontinued from the study (therapeutic-dose cohort). All patients except one (n = 12/13 [92%]) were independent of permanent ventilatory support (Table 3). This one patient, in the low-dose cohort, required invasive ventilatory support; this patient received an endotracheal tube via tracheostomy starting on Day 507 of the study, which was ongoing at data cutoff.
Table 3.
Ventilatory support.
| Type of ventilatory support | Low dose (n = 3) | Therapeutic dose (n = 10) | Total (N = 13) |
|---|---|---|---|
| Patients remaining independent of ventilatory support, n (%)a | 0 | 5 (50) | 5 (39) |
| Patients remaining independent of permanent ventilatory support, n (%)b | 2 (67) | 10 (100) | 12 (92) |
| Invasive ventilatory support, n (%) | 1 (33) | 0 | 1 (8) |
| Endotracheal tube via mouth or nose, n (%) | |||
| Yes | 0 | 0 | 0 |
| No | 3 (100) | 10 (100) | 13 (100) |
| Endotracheal tube via tracheostomy, n (%) | |||
| Yes | 1 (33) | 0 | 1 (8) |
| No | 2 (67) | 10 (100) | 12 (92) |
| Non-invasive ventilatory support, n (%) | 3 (100) | 5 (50) | 8 (62) |
| BiPAP | |||
| Yes | 3 (100) | 5 (50) | 8 (62) |
| No | 0 | 5 (50) | 5 (39) |
| Change from baseline (h) for non-invasive ventilatory support per dayc | |||
| n | 1 | 2 | 3 |
| Mean (SD) | −1·0 | 0 | −0·3 (0·6) |
| Cough assist | |||
| Yes | 3 (100) | 8 (80) | 11 (85) |
| No | 0 | 2 (20) | 2 (15) |
Percentages are based on the number of patients in the full analysis set.
BIPAP, bilevel positive airway pressure; h, hour; SD, standard deviation.
A patient was considered independent of ventilatory support if she/he did not receive any invasive or non-invasive ventilatory support at their most recent assessment. All information presented in this table corresponds to the most recent assessment.
Permanent ventilatory support was defined by tracheostomy or by requirement of at least 16 h of respiratory assistance per day (via non-invasive ventilatory support) for at least 14 consecutive days in absence of an acute reversible illness, excluding perioperative ventilation.
For the change from baseline for the number of hours of non-invasive ventilatory support per day, patients receiving at least a few hours of non-invasive ventilatory support at both study LT-001 baseline and at their most recent assessment were included. If non-invasive ventilatory support started on or prior to LT-001 baseline and was ongoing until the most recent assessment, and there was no change in the number of hours of support provided, the change was considered to be zero. Patients could be counted in more than one ventilatory support type category.
Non-invasive ventilatory support
All patients in the low-dose cohort (n = 3/3) and five patients in the therapeutic-dose cohort (n = 5/10) required non-invasive ventilatory support, which included the use of bilevel positive airway pressure ventilators (Table 3).
Nutrition or feeding support requirements
All patients in the low-dose cohort (n = 3/3) required nutrition or feeding support described as non-oral food intake that accounted for most of their daily food intake (76%–100%) (Supplementary Table S6), and all patients in the low-dose cohort (n = 3/3) had gastrostomy tube with Nissen fundoplication. Of the six patients in the therapeutic-dose cohort who required nutrition/feeding support, two had non-oral food intake that comprised most of their daily consumption (76%–100%). Three patients in the therapeutic-dose cohort had gastrostomy tube with Nissen fundoplication, and three had gastrostomy tube without Nissen fundoplication.
Four patients in the therapeutic-dose cohort remained independent of nutrition/feeding support at the end of the initial 5-year follow-up phase. No trends were found for age at treatment or add-on therapy and nutritional/feeding support needs for these patients, because there was a wide range of ages for those who remained independent of nutritional/feeding support and those who required nutritional/feeding support (data not shown). Similarly, add-on treatment does not seem to be associated with being free of nutritional support (data not shown).
Motor milestones
At their last visit in the long-term follow-up, all patients in the therapeutic-dose cohort (including those who discontinued early) (n = 10/10) continued to demonstrate in LT-001 the highest motor milestone that they had demonstrated in START, though motor milestone criteria between studies slightly differed (Supplementary Table S7). All motor milestones demonstrated at study visits during LT-001 are presented in Table 4. Two patients in the low-dose cohort, including one patient who required invasive ventilatory support, did not demonstrate any motor milestones. Two patients demonstrated a new motor milestone of standing with assistance in LT-001 (both patients were in the therapeutic-dose cohort and achieved this milestone without add-on therapy). The highest motor milestones demonstrated in LT-001 were sitting with support (n = 1/3, low-dose cohort), sitting without support (n = 5/10, therapeutic-dose cohort), standing with assistance (n = 3/10, therapeutic-dose cohort), and walking alone (n = 2/10, therapeutic-dose cohort).
Table 4.
Motor milestones.
| Developmental milestone item, n (%)a | Low dose (n = 3) | Therapeutic dose (n = 10) | Total (N = 13) |
|---|---|---|---|
| Controlling head while upright | 1 (33) | 10 (100) | 11 (85) |
| Sitting with support | 1 (33) | 10 (100) | 11 (85) |
| Sitting without support | 0 | 10 (100) | 10 (77) |
| Hands-and-knees crawling | 0 | 2 (20) | 2 (15) |
| Pulling to stand | 0 | 2 (20) | 2 (15) |
| Standing with assistance | 0 | 5 (50) | 5 (39) |
| Standing alone | 0 | 2 (20) | 2 (15) |
| Walking with assistance | 0 | 2 (20) | 2 (15) |
| Walking alone | 0 | 2 (20) | 2 (15) |
BSID-III, Bayley-III Scales of Infant and Toddler Development; WHO MGRS, World Health Organization Multicentre Growth Reference Study.
Demonstration of motor milestones was assessed by BSID-III gross motor items #4 (head control), #19 (sitting with support), #26 (sitting without support before June 17, 2022), and #35 (pulling to stand) and by WHO MGRS (sitting without support on or after June 17, 2022, crawling, standing with assistance or alone, and walking with assistance or alone).
Discussion
LT-001 provides long-term safety and efficacy follow-up data for patients from the START study who received intravenous onasemnogene abeparvovec, representing the longest duration of follow-up data for these patients published to date. Symptomatic patients with SMA type 1 continued to demonstrate a favourable benefit–risk profile and sustained efficacy for up to 10 years post-dose with or without add-on therapy. No new or emerging safety signals were reported, and the most frequently reported SAEs are common for patients with SMA (acute respiratory failure, dehydration, and pneumonia). All patients (n = 13/13) were alive at data cutoff or last visit before discontinuation. All patients in the therapeutic-dose cohort (n = 10/10) continued to demonstrate the same highest motor milestones in LT-001 as those they demonstrated in START, though motor milestone criteria differed slightly between studies. In addition, two patients demonstrated standing with assistance for the first time in LT-001; these patients were not receiving add-on therapy.
All patients except one in the low-dose cohort (n = 2/3) were independent of permanent ventilatory support. These ventilatory support endpoints are especially crucial for symptomatic patients with SMA and two SMN2 copies. Permanent ventilatory support via invasive methods has the potential to lead to serious health complications, reduced quality of life, or continued respiratory decline.24 A literature review that summarised real-world evidence from four studies indicated a reduction from baseline in invasive mechanical ventilation via tracheostomy and/or non-invasive ventilatory support for 29% (n = 12/41) of patients and discontinuation of non-invasive ventilatory support for 5% (n = 2/41) of patients treated with onasemnogene abeparvovec.17,25, 26, 27, 28 Another real-world evidence study of onasemnogene abeparvovec treatment for patients with SMA (N = 25) reported a reduction in ventilation time per day and a decrease in respiratory-related hospitalizations by 26% at 1 year after treatment.29 It is possible that, considering the wide variation in symptom severity for patients with two SMN2 gene copies, the patients reported in real-world studies had slightly more severe symptoms at the time of dosing compared with patients in LT-001.
While these results are promising for symptomatic patients with SMA, it should be noted that early treatment is pivotal, particularly for patients with one or two SMN2 copies, so as to manage the rapid and severe motor neuron loss and progression of muscular weakness that can occur in newborn patients with SMA.30 For instance, a prospective cohort study found that in newborns with two SMN2 copies (n = 21), higher gestational age at birth was associated with clinical manifestations of SMA, as well as lower motor function and lower activity with muscle electrophysiology testing.30 While early treatment before symptoms present is ideal, our findings here indicate that patients who are symptomatic may also benefit from treatment.
This follow-up study, LT-001, is limited by the small sample size and the number of patients who discontinued the study early. In terms of discontinuation, several documented attempts were made to reach out to patients who were lost to follow-up. As loss of patients to follow-up is expected over an extensive time period similar to that of this 15-year study, mitigation attempts were made in reimbursing travel expenses over the 5 years of in-person visits and switching to telephone calls for patient/caregiver convenience. Only SAEs and AESI were collected, rather than all AEs. Further, the study was not blinded, potentially introducing a bias for patients, caregivers, or physicians in reporting outcomes. Inclusion of a comparator arm was not feasible considering the long-term nature of this study. However, several phase 3 and 4 studies and real-world evidence have demonstrated a positive benefit–risk profile with onasemnogene abeparvovec for both symptomatic and presymptomatic patients with SMA.31, 32, 33, 34, 35, 36
In addition, the interpretation of results is confounded by treatment with nusinersen and/or risdiplam for several patients, especially considering that reasons for add-on therapy were not collected; therefore, it is unclear whether add-on therapy was initiated because of lack of efficacy or functional decline. However, there is no evidence from clinical trial data or real-world studies indicating that combination therapy is more effective than onasemnogene abeparvovec monotherapy. While some observational studies or case reports may have suggested potential benefits of combination therapy, these studies were limited by nonrandomized designs, heterogeneous patient populations, variable timing relative to symptom onset/gene therapy administration, and potential confounding factors.37, 38, 39, 40, 41, 42 Comparative studies with appropriate control groups, predefined endpoints, and adequate follow-up are needed to establish whether combination therapy is more effective than onasemnogene abeparvovec monotherapy.
In this analysis of the ongoing, long-term follow-up of patients from the START clinical trial, a single intravenous dose of onasemnogene abeparvovec for patients with symptomatic SMA type 1 resulted in sustained efficacy for up to 10 years post-dose, with or without add-on therapy. No new or emerging safety signals were reported during long-term follow-up. The safety profile continues to be favourable and consistent with the known safety profile of onasemnogene abeparvovec. While several phase 3 and 4 studies have evaluated the use of onasemnogene abeparvovec for patients with SMA, further research may build on these long-term findings in a larger population. The LT-001 study results provide support for the favourable benefit–risk profile of onasemnogene abeparvovec in the treatment of symptomatic patients with SMA type 1.
Contributors
All authors had full access to and analysed and interpreted the data, participated in the development and critical review of the manuscript, approved the final version of the manuscript submission for publication, and are accountable for the accuracy and integrity of the work. LY, MAW, RAC, ECB, and AMC have access to and have verified the underlying study data.
Concept and design: LM.
Analysis and interpretation of data: RBE, LY, LM, AI.
Drafting of the manuscript: MAW, RBE, LY, RAC, ECB, LM, AI, AMC.
Critical revision of the paper for important intellectual content: MAW, RBE, LY, RAC, ECB, LM, AI, AMC.
Administrative, technical, or logistic support: RBE, LY, LM, AI.
Other (verification of study data): LY.
Data sharing statement
Novartis is committed to sharing, upon requests from qualified external researchers and subsequent approval by an independent review panel based upon scientific merit, anonymised patient-level and study-level clinical trial data, and redacted clinical study reports, for medicines and indications approved in the United States of America and Europe after the respective study is accepted for publication. All data provided are anonymised to respect the privacy of participants who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Declaration of interests
MAW has received personal compensation from Novartis Gene Therapies, Inc./Novartis Pharma AG for advisory board activities, and personal compensation from Sarepta Therapeutics and Catalyst Pharmaceuticals for consulting activities.
RBE is an employee of Novartis and owns stock/other equities.
LY is an employee of Novartis and owns stock/other equities.
RAC reports nothing to disclose.
ECB reports nothing to disclose.
LM is an employee of Novartis and owns stock/other equities.
AI is an employee of Novartis and owns stock/other equities.
AMC has received personal compensation for serving on a Scientific Advisory/Data Safety Monitoring board for Genentech Roche, Edgewise Therapeutics, Dyne Therapeutics, Octapharma, and Catabasis.
Acknowledgements
All financial and material support for this study was provided by Novartis Pharma AG, Basel, Switzerland. The authors wish to thank the investigators and, most importantly, all of the patients, families, and caregivers for their willingness to participate in this study, which is sponsored by Novartis Pharma AG. Writing and editing assistance, including preparation of a draft manuscript under the direction and guidance of the authors, incorporating author feedback, and manuscript submission, was provided by Caryne Craige, PhD (Kay Square Scientific, Butler, PA, USA). This support was funded by Novartis Pharma AG, Basel, Switzerland.
Footnotes
Supplementary data related to this article can be found at https://doi.org/10.1016/j.eclinm.2026.103867.
Appendix A. Supplementary data
References
- 1.Prior T.W., Leach M.E., Finanger E.L. In: GeneReviews®. Adam M.P., Feldman J., Mirzaa G.M., et al., editors. University of Washington; 1993–2025; 2024. Spinal muscular atrophy.https://www.ncbi.nlm.nih.gov/books/NBK1352 [Google Scholar]
- 2.Wirth B., Karakaya M., Kye M.J., Mendoza-Ferreira N. Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next. Annu Rev Genomics Hum Genet. 2020;21:231–261. doi: 10.1146/annurev-genom-102319-103602. [DOI] [PubMed] [Google Scholar]
- 3.Kolb S.J., Kissel J.T. Spinal muscular atrophy: a timely review. Arch Neurol. 2011;68(8):979–984. doi: 10.1001/archneurol.2011.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Aragon-Gawinska K., Mouraux C., Dangouloff T., Servais L. Spinal muscular atrophy treatment in patients identified by newborn careening: a systematic review. Genes. 2023;14(7):1377. doi: 10.3390/genes14071377. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Glascock J., Sampson J., Haidet-Phillips A., et al. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. J Neuromuscul Dis. 2018;5(2):145–158. doi: 10.3233/JND-180304. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Mercuri E., Finkel R.S., Muntoni F., et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103–115. doi: 10.1016/j.nmd.2017.11.005. [DOI] [PubMed] [Google Scholar]
- 7.Angilletta I., Ferrante R., Giansante R., et al. Spinal muscular atrophy: an evolving scenario through new perspectives in diagnosis and advances in therapies. Int J Mol Sci. 2023;24(19) doi: 10.3390/ijms241914873. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Mailman M.D., Heinz J.W., Papp A.C., et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med. 2002;4:20–26. doi: 10.1097/00125817-200201000-00004. [DOI] [PubMed] [Google Scholar]
- 9.Kolb S.J., Coffey C.S., Yankey J.W., et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883–891. doi: 10.1002/ana.25101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Wijngaarde C.A., Stam M., Otto L.A.M., et al. Population-based analysis of survival in spinal muscular atrophy. Neurology. 2020;94(15):e1634–e1644. doi: 10.1212/WNL.0000000000009248. [DOI] [PubMed] [Google Scholar]
- 11.Finkel R.S., McDermott M.P., Kaufmann P., et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810–817. doi: 10.1212/WNL0000000000000741. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Evrysdi Prescribing information. Genentech. 2026. https://www.gene.com/download/pdf/evrysdi_prescribing.pdf
- 13.Spinraza Prescribing information. Biogen. 2026. https://www.spinraza.com/content/dam/commercial/spinraza/caregiver/en_us/pdf/spinraza-prescribing-information.pdf
- 14.Zolgensma Prescribing information. Novartis. 2025. https://www.novartis.com/us-en/sites/novartis_us/files/zolgensma.pdf
- 15.Finnegan R., Rohwer A.M., Scoto M., et al. Mortality of symptomatic children with spinal muscular atrophy in the era of disease-modifying therapies. Neuromuscul Disord. 2025;49 doi: 10.1016/j.nmd.2025.105313. [DOI] [PubMed] [Google Scholar]
- 16.Mercuri E., Cicala G., Villa M., Pera M.C. What did we learn from new treatments in SMA? A narrative review. Acta Myol. 2025;44(1):28–32. doi: 10.36185/2532-1900-1043. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Waldrop M.A., Karingada C., Storey M.A., et al. Gene therapy for spinal muscular atrophy: safety and early outcomes. Pediatrics. 2020;146(3) doi: 10.1542/peds.2020-0729. [DOI] [PubMed] [Google Scholar]
- 18.Mendell J.R., Al-Zaidy S., Shell R., et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713–1722. doi: 10.1056/NEJMoa1706198. [DOI] [PubMed] [Google Scholar]
- 19.Gene transfer clinical trial for spinal muscular atrophy type 1. ClinicalTrials.gov identifier: NCT02122952. 2022. https://clinicaltrials.gov/ct2/show/NCT02122952
- 20.Mendell J.R., Al-Zaidy S.A., Lehman K.J., et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021;78(7):834–841. doi: 10.1001/jamaneurol.2021.1272. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Long-term Follow-up study for patients from AVXS-101-CL-101 (START). ClinicalTrials.gov identifier: NCT03421977. 2025. https://clinicaltrials.gov/study/NCT03421977
- 22.WHO Multicentre Growth Reference Study Group WHO Motor Development Study: windows of achievement for six gross motor development milestones. Acta Paediatr Suppl. 2006;450:86–95. doi: 10.1111/j.1651-2227.2006.tb02379.x. [DOI] [PubMed] [Google Scholar]
- 23.Bayley N. 3rd ed. Harcourt Assessment; 2006. Bayley Scales of Infant and Toddler Development: Administration Manual. [Google Scholar]
- 24.Lagae L., Proesmans M., Van den Hauwe M., Vermeulen F., De Waele L., Boon M. Respiratory morbidity in patients with spinal muscular atrophy-a changing world in the light of disease-modifying therapies. Front Pediatr. 2024;12 doi: 10.3389/fped.2024.1366943. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Panagiotou P., Kanaka-Gantenbein C., Kaditis A.G. Changes in ventilatory support requirements of spinal muscular atrophy (SMA) patients post gene-based therapies. Children. 2022;9(8):1207. doi: 10.3390/children9081207. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Weiß C., Ziegler A., Becker L.L., et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health. 2022;6(1):17–27. doi: 10.1016/S2352-4642(21)00287-X. [DOI] [PubMed] [Google Scholar]
- 27.D'Silva A.M., Holland S., Kariyawasam D., et al. Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy. Ann Clin Transl Neurol. 2022;9(3):339–350. doi: 10.1002/acn3.51519. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Matesanz S.E., Curry C., Gross B., et al. Clinical course in a patient with spinal muscular atrophy type 0 treated with nusinersen and onasemnogene abeparvovec. J Child Neurol. 2020;35(11):717–723. doi: 10.1177/0883073820928784. [DOI] [PubMed] [Google Scholar]
- 29.Lavie M., Rochman M., Armoni Domany K., et al. Respiratory outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy: national real-world cohort study. Eur J Pediatr. 2024;184(1):58. doi: 10.1007/s00431-024-05886-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Farrar M.A., Mandarakas M., Briggs N., et al. Gestational age at birth and clinical manifestations of spinal muscular atrophy. Neurology. 2025;105(2) doi: 10.1212/WNL.0000000000213799. [DOI] [PubMed] [Google Scholar]
- 31.Strauss K.A., Farrar M.A., Muntoni F., et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med. 2022;28(7):1390–1397. doi: 10.1038/s41591-022-01867-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Strauss K.A., Farrar M.A., Muntoni F., et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022;28(7):1381–1389. doi: 10.1038/s41591-022-01866-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Mercuri E., Muntoni F., Baranello G., et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(10):832–841. doi: 10.1016/S1474-4422(21)00251-9. [DOI] [PubMed] [Google Scholar]
- 34.Day J.W., Finkel R.S., Chiriboga C.A., et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284–293. doi: 10.1016/S1474-4422(21)00001-6. [DOI] [PubMed] [Google Scholar]
- 35.Saute J.A., Muntadas J., Gurgel-Giannetti J., et al. Safety and tolerability of onasemnogene abeparvovec for patients with spinal muscular atrophy weighing ≤17 kg and ≤24 months old from OFELIA, a phase 4, open-label, multicenter, non-randomised, interventional study. Lancet Reg Health, Am. 2025;49 doi: 10.1016/j.lana.2025.101193. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Servais L., Day J.W., De Vivo D.C., et al. Real-world outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: findings from the RESTORE registry. J Neuromuscul Dis. 2024;11(2):425–442. doi: 10.3233/JND-230122. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Harada Y., Rao V.K., Arya K., et al. Combination molecular therapies for type 1 spinal muscular atrophy. Muscle Nerve. 2020;62(4):550–554. doi: 10.1002/mus.27034. [DOI] [PubMed] [Google Scholar]
- 38.Bitetti I., Manna M.R., Stella R., Varone A. Zolgensma® and risdiplam in a paediatric patient with spinal muscular atrophytype 1: a case report. Acta Myol. 2023;42(2–3):82–85. doi: 10.36185/2532-1900-356. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Bemanalizadeh M., Heidary L., Dakkali M.S., et al. Combination therapies in spinal muscular atrophy: a systematic review. Eur J Pediatr. 2025;184(9):583. doi: 10.1007/s00431-025-06386-0. [DOI] [PubMed] [Google Scholar]
- 40.Chrościńska-Krawczyk M., Kozioł I., Zienkiewicz E. Real-world experience with switch to onasemnogene abeparvovec after initial therapy with nusinersen or risdiplam. Neuromuscul Disord. 2025;55 doi: 10.1016/j.nmd.2025.105454. [DOI] [PubMed] [Google Scholar]
- 41.Svoboda M.D., Kuntz N., Leon-Astudillo C., et al. Risdiplam treatment following onasemnogene abeparvovec in individuals with spinal muscular atrophy: a multicenter case series. BMC Neurol. 2025;25(1):283. doi: 10.1186/s12883-025-04276-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Mirea A., Shelby E.S., Axente M., et al. Combination therapy with nusinersen and onasemnogene abeparvovec-xioi in spinal muscular atrophy type I. J Clin Med. 2021;10(23):5540. doi: 10.3390/jcm10235540. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.

